Skip to main content


  • Oral presentation
  • Open Access

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile

  • 1,
  • 1,
  • 2,
  • 1 and
  • 1
Journal of the International AIDS Society201013 (Suppl 4) :O49

  • Published:


  • Resistant Virus
  • Resistance Profile
  • Recombinant Form
  • Etravirine
  • Associate Mutation

Purpose of the study

Lersivirine (UK-453,051), a new potent NNRTI, displays novel binding with a unique in vitro resistance profile, and shows potential for use against transmitted NNRTI resistant virus and as a candidate for sequential NNRTI therapy. Further in vitro analyses have been performed to establish the breadth of activity and identify potential populations that might benefit from lersivirine therapy. Lersivirine activity against various HIV-1 subtypes and viruses with decreased susceptibility to etravirine (ETR) were characterised.


The PhenoSense™ assay was used to assess the antiviral activity of lersivirine against different HIV-1 subtypes (A, A1, B, BF, C, C/H, D, F, F1, G and H), and the circulating recombinant forms (CRFs) CRF01_AE and CRF02_AG. All were obtained from treatment-naïve patients. Nineteen additional clinical viruses with NNRTI resistance associated mutations (RAMs) were selected based on their reduced susceptibility to ETR.

Summary of results

Lersivirine was active against a panel of 80 clinically- derived viruses representing subtypes A to H, including several CRFs, from a range of geographical origins (geometric mean IC50 fold change [FC] to reference virus was 0.92). IC50 FC were < 2 for all viruses with the exception of 1 subtype BF and 1 subtype C (geometric mean IC50 FC: subtype BF = 0.98, 95% CI 0.64 - 1.49, n=7; subtype C = 1.07, 95% CI 0.88 - 1.30, n=25). Lersivirine retained activity (< 10 FC IC50) for 11 of the 19 viruses with ETR resistance (> 2.9 FC IC50, lower clinical cut-off). Overall, a direct correlation between lersivirine and ETR susceptibility was not found (R2 = 0.002). This is consistent with different genotypic resistance profiles. Indeed to date, reduced susceptibility to lersivirine and ETR is associated with the presence of different specific NNRTI RAMs.


Lersivirine showed comparable activity across a range of viruses representing subtypes A to H. The activity of lersivirine against ETR- resistant viruses reflects significant differences in the resistance profiles of lersivirine and ETR consistent with the unique binding of lersivirine in the NNRTI binding pocket. Lersivirine has a distinctive in vitro resistance profile and may provide an additional therapy choice for patients with evidence of NNRTI resistance.

Authors’ Affiliations

Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, UK
Pfizer Global Research and Development, New London, USA


© Mori et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.